AGP
TVTX icon

Artia Global Partners’s Travere Therapeutics TVTX Stock Holding History

Artia Global Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3M Buy
339,033
+268,333
+380% +$11.9M 3.55% 8
2026
Q1 		$2.1M Hold
70,700
– – 0.42% 37
2025
Q4 		$2.7M Buy
70,700
+39,800
+129% +$1.29M 0.38% 34
2025
Q3 		$739K Hold
30,900
– – 0.12% 46
2025
Q2 		$457K Hold
30,900
– – 0.11% 37
2025
Q1 		$554K Buy
+30,900
New +$627K 0.14% 33

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Artia Global Partners's TVTX Position: Q2 2026 in Review

Artia Global Partners increased its Travere Therapeutics (TVTX) stake by 380% in Q2 2026, buying an estimated $11.9M and bringing the position to 339,033 shares worth $19.3M. The position accounts for 3.55% of the portfolio, ranked #8.

Artia Global Partners first reported a position in TVTX in Q1 2025 and has held it in 6 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Artia Global Partners held 339,033 shares of Travere Therapeutics worth $19.3M as of Q2 2026.
  • Artia Global Partners bought 268,333 Travere Therapeutics shares in Q2 2026, an estimated $11.9M.
  • Travere Therapeutics made up 3.55% of Artia Global Partners's portfolio in Q2 2026, its #8 holding.
  • Artia Global Partners first reported a position in Travere Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.